Skip to main content

CLINICAL TRIAL article

Front. Med.
Sec. Ophthalmology
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1497501
This article is part of the Research Topic New Concepts, Advances, and Future Trends in Clinical Research on Eye Diseases View all 9 articles

Photobiomodulation Therapy for Congenital Color Vision Deficiency: Results of a Preliminary Randomized Clinical Trial

Provisionally accepted
Yidi Liu Yidi Liu 1Qinghua Yang Qinghua Yang 2Jun Yu Jun Yu 3*Liang Jia Liang Jia 2*
  • 1 Department of Laser Medicine, the First Medical Center, Chinese PLA General Hospital, Beijing, China
  • 2 Department of Ophthalmology, The Third Medical Center of Chinese PLA General Hospital, Yuzhong, Chongqing, China
  • 3 Yiwu Aier Eye Hospital, Jinhua, Zhejiang Province, China

The final, formatted version of the article will be published soon.

    Purpose: this study presents a novel randomized controlled trial investigating photobiomodulation (PBM) therapy as an intervention method for color vision deficiency (CVD).Methods: a total of 74 participants with CVD were assigned to either the PBM group or the control group. In the PBM group, participants wore virtual reality (VR) goggles twice daily, with a 12-hour interval, over a four-week period. The VR video consisted of alternating red and green images, each presented for five seconds, totaling six minutes and twenty seconds. No treatment was administered to the control group. Color vision improvement was assessed using Yu's, Ishihara's pseudoachromatic plates, Color Blindness Check (CBC), and FM-100 Hue total error score (TES).Results: after 4 weeks, in terms of Yu's and Ishihara's Plates, the patients in PBM group could identify increasing pieces (before: 1.6±1.6, 2.3±2.2; 4 weeks: 6.5±4.4, 5.4±2.9), while in control group, the number was before: 2.6±3.4, 2.6±2.5; 4 weeks: 3.3±3.6, 2.9±2.2. As for CBC scores, the patients in PBM also showed improved high scores (before:2353.3±700.0; 4 weeks: 2693.6±642.5). Moreover, PBM treatment resulted in a significant reduction of FM-100 scores (before: 298.0±211.3; 4 weeks: 202.1±114.4).Conclusions: these findings suggest that PBM therapy holds promise as a potential treatment option for individuals with CVD.

    Keywords: color vision deficiency, Deutan, Protan, photobiomodulation, Phototherapy

    Received: 17 Sep 2024; Accepted: 02 Dec 2024.

    Copyright: © 2024 Liu, Yang, Yu and Jia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Jun Yu, Yiwu Aier Eye Hospital, Jinhua, 322001, Zhejiang Province, China
    Liang Jia, Department of Ophthalmology, The Third Medical Center of Chinese PLA General Hospital, Yuzhong, 400042, Chongqing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.